473795-30-1

Basic information

• Product Name: Carbamic acid, [(3R,4S)-4-(2-hydroxyethyl)-1-(phenylmethyl)-3-pyrrolidinyl]-, 1,1-dimethylethyl ester
• CAS NO: 473795-30-1
• Molecular Formula: C18H28N2O3
• Molecular Weight: 320.432
• Mol File: 473795-30-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [(3R,4S)-4-(2-hydroxyethyl)-1-(phenylmethyl)-3-pyrrolidinyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(3R,4S)-4-(2-hydroxyethyl)-1-(phenylmethyl)-3-pyrrolidinyl]-, 1,1-dimethylethyl ester(473795-30-1)
• EPA Substance Registry System: Carbamic acid, [(3R,4S)-4-(2-hydroxyethyl)-1-(phenylmethyl)-3-pyrrolidinyl]-, 1,1-dimethylethyl ester(473795-30-1)

Safety Data

• Hazardous Substances Data: 473795-30-1(Hazardous Substances Data)

Upstream product

• 100-46-9 benzylamine 
• 129975-11-7 ethyl (E)-4-benzylaminocrotonate 
• 34619-03-9 tert-butyldicarbonate 

Downstream Products

• 473795-32-3 exo 3-(tert-butoxycarbonylamino)-1-azabicyclo[2.2.1]heptane 
• 688790-05-8 exo 3-(tert-butoxycarbonylamino)-1-azabicyclo[2.2.1]heptane 
• 688790-05-8 (3R,4S)-3-(tert-butoxycarbonylamino)-1-azabicyclo[2.2.1]heptane 
• 508209-67-4 (3S,4R)-1-azabicyclo[2.2.1]heptan-3-amine 

Relevant articles and documents

1H-PYRAZOLE AND 1H-PYRROLE-AZABICYCLIC COMPOUNDS WITH ALFA-7 NACHR ACTIVITY

The invention provides compounds of Formula (I), wherein Azabicyclo is Formula (I, II, III, IV, V, VI, VII); W is Formula (m); where the variables have the definitions discussed herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat a disease or condition in which α7 is known to be involved.

COMPOUNDS AS RADIOLIGANDS FOR THE DIAGNOSIS OF DISEASE

Radiolabeled ligands useful as probes for determining the relative abundance, receptor occupancy, and/or function of nicotinic acetylcholine receptors. The compounds of Formula I as described herein are labeled with a radioactive isotopic moiety such as 11C, 18F, 76Br, 123I or 125I. Disorders are diagnosed by administering to a mammal a detectably labeled compound and detecting the binding of that compound to the nAChR. The compounds that have been administered are detected using methods including, but not limited to, position emission topography and single-photon to emission computed tomography. The present invention is useful in diagnosing a wide variety of diseases and disorders as discussed herein.

Azabicyclic compounds for the treatment of disease

The invention provides compounds of Formula I: 1wherein Azabicyclo is 2These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which α7 is known to be involved.